Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9325910 | 0.84 | ADRA2A (0.43) | TSHRADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL9325876 | 0.83 | CYP2E1 (0.34) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL9324682 | 0.82 | TSHR (0.35) | TSHRADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL9325885 | 0.81 | ADRA2A (0.35) | TSHRADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL9326270 | 0.80 | CDK5 (0.40) | — | |
| SCHEMBL9325681 | 0.75 | ADRA2A (0.38) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL9324722 | 0.69 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL9325735 | 0.68 | ADRA2A (0.42) | TSHRADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL9325707 | 0.66 | CYP2E1 (0.35) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL9325689 | 0.66 | CYP2E1 (0.35) | ADRA2AADRA2BADRA2CADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0532553-B1 | USE OF COMPOUNDS FOR THE TREATMENT OF AGE-RELATED MEMORY IMPAIRMENT AND OTHER COGNITIVE DISORDERS | ORION YHTYMAE OY (FI) | 1997-08-13 | — | — | EP | claimed |
| US-5434177-A | Imidazoles for the treatment of age-related cognitive disorders and alzheimer | ORION-YHTYMA OY (FI) | 1995-07-18 | — | — | US | claimed |
| EP-0372954-B1 | Substituted imidazole derivatives and their preparation and use | ORION YHTYMAE OY (FI) | 1994-03-09 | — | — | EP | claimed |
| US-5292887-A | Antgonists at postsynoptic adrenoreceptors; hypotensive and antidiabetic agents | FARMOS-YHTYMA OY (FI) | 1994-03-08 | — | — | US | claimed |
| EP-0532553-A1 | COMPOUNDS FOR THE TREATMENT OF AGE-RELATED MEMORY IMPAIRMENT AND OTHER COGNITIVE DISORDERS. | ORION YHTYMAE OY (FI) | 1993-03-24 | — | — | EP | claimed |
| WO-1991018886-A1 | COMPOUNDS FOR THE TREATMENT OF AGE-RELATED MEMORY IMPAIRMENT AND OTHER COGNITIVE DISORDERS | Orion-Yhtymä Oy (FI) | 1991-12-12 | — | — | WO | claimed |
| EP-0372954-A1 | Substituted imidazole derivatives and their preparation and use | ORION-YHTYMÀ OY (FI) | 1990-06-13 | — | — | EP | claimed |
| EP-0532553-B1 | USE OF COMPOUNDS FOR THE TREATMENT OF AGE-RELATED MEMORY IMPAIRMENT AND OTHER COGNITIVE DISORDERS | ORION YHTYMAE OY (FI) | 1997-08-13 | — | — | EP | disclosed |
| US-5434177-A | Imidazoles for the treatment of age-related cognitive disorders and alzheimer | ORION-YHTYMA OY (FI) | 1995-07-18 | — | — | US | disclosed |
| EP-0372954-B1 | Substituted imidazole derivatives and their preparation and use | ORION YHTYMAE OY (FI) | 1994-03-09 | — | — | EP | disclosed |
| US-5292887-A | Antgonists at postsynoptic adrenoreceptors; hypotensive and antidiabetic agents | FARMOS-YHTYMA OY (FI) | 1994-03-08 | — | — | US | disclosed |
| WO-1991018886-A1 | COMPOUNDS FOR THE TREATMENT OF AGE-RELATED MEMORY IMPAIRMENT AND OTHER COGNITIVE DISORDERS | Orion-Yhtymä Oy (FI) | 1991-12-12 | — | — | WO | disclosed |
| EP-0372954-A1 | Substituted imidazole derivatives and their preparation and use | ORION-YHTYMÀ OY (FI) | 1990-06-13 | — | — | EP | disclosed |